30430356|t|Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives.
30430356|a|Amyotrophic lateral sclerosis (ALS) is a clinically heterogeneous disorder characterized by degeneration of upper motor neurons in the brainstem and lower motor neurons in the spinal cord. Multiple mechanisms of motor neuron injury have been implicated, including more than 20 different genetic factors. The pathogenesis of ALS consists of two stages: an early neuroprotective stage and a later neurotoxic. During early phases of disease progression, the immune system through glial and T cell activities provides anti-inflammatory factors that sustain motor neuron viability. As the disease progresses and motor neuron injury accelerates, a rapidly succeeding neurotoxic phase develops. A well-orchestrated purine-mediated dialog among motor neurons, surrounding glia and immune cells control the beneficial and detrimental activities occurring in the nervous system. In general, low adenosine triphosphate (ATP) concentrations protect cells against excitotoxic stimuli through purinergic P2X4 receptor, whereas high concentrations of ATP trigger toxic P2X7 receptor activation. Finally, adenosine is also involved in ALS progression since A2A receptor antagonists prevent motor neuron death. Given the complex cellular cross-talk occurring in ALS and the recognized function of extracellular nucleotides and adenosine in neuroglia communication, the comprehensive understanding of purinome dynamics might provide new research perspectives to decipher ALS and help to design more efficient and targeted drugs. This review will focus on the purinergic players involved in ALS etiology and disease progression and current therapeutic strategies to enhance neuroprotection and suppress neurotoxicity.
30430356	0	10	Purinergic	Chemical	-
30430356	26	55	amyotrophic lateral sclerosis	Disease	MESH:D000690
30430356	114	143	Amyotrophic lateral sclerosis	Disease	MESH:D000690
30430356	145	148	ALS	Disease	MESH:D000690
30430356	326	345	motor neuron injury	Disease	MESH:D016472
30430356	438	441	ALS	Disease	MESH:D000690
30430356	509	519	neurotoxic	Disease	MESH:D020258
30430356	633	645	inflammatory	Disease	MESH:D007249
30430356	721	740	motor neuron injury	Disease	MESH:D016472
30430356	775	785	neurotoxic	Disease	MESH:D020258
30430356	822	828	purine	Chemical	MESH:C030985
30430356	999	1021	adenosine triphosphate	Chemical	MESH:D000255
30430356	1023	1026	ATP	Chemical	MESH:D000255
30430356	1065	1076	excitotoxic	Disease	
30430356	1093	1103	purinergic	Chemical	-
30430356	1150	1153	ATP	Chemical	MESH:D000255
30430356	1168	1181	P2X7 receptor	Gene	5027
30430356	1203	1212	adenosine	Chemical	MESH:D000241
30430356	1233	1236	ALS	Disease	MESH:D000690
30430356	1255	1258	A2A	DNAMutation	tmVar:c|SUB|A|2|A;HGVS:c.2A>A;VariantGroup:0;CorrespondingGene:5027;CorrespondingSpecies:9606
30430356	1301	1306	death	Disease	MESH:D003643
30430356	1359	1362	ALS	Disease	MESH:D000690
30430356	1424	1433	adenosine	Chemical	MESH:D000241
30430356	1567	1570	ALS	Disease	MESH:D000690
30430356	1655	1665	purinergic	Chemical	-
30430356	1686	1689	ALS	Disease	MESH:D000690
30430356	1798	1811	neurotoxicity	Disease	MESH:D020258
30430356	Association	HGVS:c.2A>A;CorrespondingGene:5027	MESH:D003643
30430356	Positive_Correlation	MESH:D000255	5027
30430356	Association	HGVS:c.2A>A;CorrespondingGene:5027	MESH:D000690
30430356	Positive_Correlation	MESH:D000241	MESH:D000690
30430356	Association	MESH:D003643	5027
30430356	Association	MESH:D000690	5027

